BerandaN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Tutup sebelumnya
R$34,32
Rentang hari
R$31,17 - R$31,56
Rentang tahun
R$30,55 - R$44,95
Kapitalisasi pasar
10,87 M USD
Volume Rata-Rata
307,00
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 627,70 jt | 21,84% |
Biaya operasional | 301,80 jt | 37,87% |
Laba bersih | 103,10 jt | -30,20% |
Margin laba bersih | 16,43 | -42,69% |
Penghasilan per saham | 1,69 | 9,74% |
EBITDA | 138,10 jt | -11,47% |
Tarif pajak efektif | 36,59% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 1,08 M | 4,31% |
Total aset | 3,72 M | 14,37% |
Total liabilitas | 1,13 M | 10,75% |
Total ekuitas | 2,59 M | — |
Saham yang beredar | 99,70 jt | — |
Harga terhadap nilai buku | 1,32 | — |
Tingkat pengembalian aset | 9,03% | — |
Tingkat pengembalian modal | 10,75% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 103,10 jt | -30,20% |
Kas dari operasi | 242,50 jt | 96,36% |
Kas dari investasi | -68,30 jt | 66,15% |
Kas dari pembiayaan | -290,00 jt | -919,21% |
Perubahan kas bersih | -116,10 jt | -172,54% |
Arus kas bebas | 220,28 jt | 138,04% |
Tentang
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
1.800
